Broad Institute

MAY 14, 2024

Then, during graduate school at the California Institute of Technology in the early 1960s, he was introduced to bacteriophage T7, a virus that infects Escherichia coli bacteria. As of 2020, the T7 technology had been cited in more than 220,000 published studies, with 12,000 new studies using the technology published each year.

RNA 84

RNA Production Molecular Biology Laboratories 84

The Pharma Data

MARCH 16, 2021

Today’s agreement with the Department of Health and Human Services (HHS) and the Department of Defense (DoD) builds on an agreement from October 2020 for the support of the late-stage development of AZD7442 and for the supply of an initial 100,000 doses of the LAAB combination. It included the option to acquire additional doses in 2021.

Treatment 52

Treatment Virus Trials Government 52

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.

Trials 52

Trials Long-Term Care Facilities Virus Government 52

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. 1 Olumiant Prescribing Information, 2020.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

NOVEMBER 11, 2020

12, 2020 14:00 UTC. As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About Selva Therapeutics.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

OCTOBER 28, 2020

28, 2020 /PRNewswire/ — . In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 TARRYTOWN, N.Y. , Regeneron has shared these results with the U.S. There was a 1.08

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

FEBRUARY 25, 2021

Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. About TicoVac (TBE vaccine, whole virus inactivated). Accessed: May 2020.

FDA 52

FDA Vaccine Virus Clinical Trials 52

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing.

Virus 52

Virus International Trials Clinical Trials 52

The Pharma Data

AUGUST 22, 2021

AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales. Antimicrob Agents Chemother.

Trials 52

Trials Pharmacokinetics Vaccine Virus 52

Codon

FEBRUARY 27, 2024

Patient YY’s neighbors quickly started to become infected, passing on the virus in turn. While the consensus that emerged among experts was that the virus spread primarily via airborne transmission , it also made use of another route: fomite transmission. Puzzled, epidemiologists sought to understand the source of the outbreak.

Virus 68

Virus Hospitals Production Regulations 68

The Pharma Data

JUNE 26, 2021

The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Preclinical results were shared previously at the 8 th annual mRNA Healthcare Conference in November 2020.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 17, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. 3,4,5,6,7). COVID-19 Vaccine AstraZeneca is known as Vaxzevria in Europe. About AstraZeneca.

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

This product was developed by uniQure prior to being licensed to CSL Behring. At the same time, it is understandably important to be able to measure and characterize a treatment’s effect over time. It seems reasonable to assume that there was some hope this would be sufficient for accelerated approval based on this surrogate endpoint.

Therapies 119

Therapies FDA FDA Approval Treatment 119

DrugBaron

NOVEMBER 9, 2020

The first death unequivocally caused by COVID was reported to the world on January 11 th 2020 – that’s just 303 days ago (even if it feels like a lifetime away). Indeed, China has already licensed a vaccine, albeit without the data that would typically be required to support such an approval.

Vaccine 100

Vaccine Pharmaceutical Companies Government Pharmaceuticals 100

The Pharma Data

AUGUST 28, 2020

UK signs deals for 90 million virus vaccine doses. The UK remains under the jurisdiction of the European Medicines Agency and its licensing scheme until the end of the Brexit transition period on 31 December 2020. Oxford coronavirus vaccine triggers immune response.

Vaccine 52

Vaccine Immune Response Nurses Government 52

The Pharma Data

JANUARY 5, 2021

Telemedicine isn’t new, but the COVID-19 pandemic has really put the technology front and center, with clinics closing for certain services after state and local governments issued stay-at-home orders to help prevent the spread of the virus. But from March through May of 2020 they jumped to 3,000 to 4,000 visits per day, Keeves said.

Doctors 52

Doctors Pharmacy Vaccine Licensing 52

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. About the Phase 1/2 clinical trial.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 31, 2021

Our preclinical work at Gritstone developing our powerful prime-boost vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are very similar to HIV-1. This press release features multimedia. View the full release here: [link]. Gilead Forward-Looking Statements.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

MARCH 29, 2022

13 People at increased risk of exposure to the SARS-CoV-2 virus could also benefit from protection with Evusheld. 1,3 The reduced Fc effector function aims to minimise the risk of antibody-dependent enhancement of disease – a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.20.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

MARCH 25, 2022

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. Evusheld was well-tolerated in the trials.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

DECEMBER 19, 2020

20, 2020 02:44 UTC. Today’s ACIP recommendation follows the December 1, 2020 ACIP recommendation for a Phase 1a rollout in which the first priority for COVID-19 vaccines is given to healthcare personnel treating patients and residents in long-term care facilities. government by the end of December 2020. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

MARCH 22, 2021

Casirivimab and imdevimab is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed by Regeneron scientists to block infectivity of SARS-CoV-2, the virus that causes COVID-19. In November 2020, the antibody cocktail was authorised by the U.S.

Clinical Trials 52

Clinical Trials Virus Trials FDA 52

The Pharma Data

APRIL 27, 2021

We remain committed to moving as quickly and safely as possible to bring this vaccine to more people in Europe, as the deadly virus continues to wreak havoc across the continent.” This brings the total number of doses to be delivered to the EU to 600 million. “We said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “To

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 28, 2020

28, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“ BetterLife ” or the “ Company ”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that it has added Mr. Sergei Stetsenko to its Board of Directors to prepare for its growth phase in psychedelic medicines. VANCOUVER, Dec.

Compliance 52

Compliance Licensing Licensing Virus 52

The Pharma Data

MARCH 26, 2021

Data from the registrational COMET-ICE trial also will form the basis for a Biologics License Application (BLA) submission to the FDA. Importantly, VIR-7832 also has been engineered to potentially enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection. About the Vir and GSK Collaboration.

Treatment 52

Treatment FDA Vaccine Trials 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. Results from the PRECISION Study Expected in First Half of 2021.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

SEPTEMBER 7, 2021

Bristol Myers Squibb has a global exclusive license to develop, manufacture and commercialize the Rockefeller University’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. We are encouraged that more than 85% of our employees in the U.S. Global Relief Efforts.

Clinical Trials 52

Clinical Trials Vaccine Virus Trials 52

Agency IQ

JANUARY 19, 2024

However, this is actually relatively aligned with the number of new active substances seen prior to and during the first year of the pandemic: 39 in 2020 ; 30 in 2019 ; 42 in 2018 and 35 in 2017. for the years 2020 to 2022. Accelerated assessments accounted for six opinions in 2020, three in 2021, five in 2022, and three in 2023.

Biosimilars 40

Biosimilars FDA Production Treatment 40

The Pharma Data

DECEMBER 20, 2020

20, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. BetterLife also announces that it has engaged GRA Enterprises LLC (the “Consultant”) to provide investor relations services pursuant to a consulting agreement dated December 15, 2020. VANCOUVER, Dec. per share, with the transaction valued at $10 million.

Production 52

Production Clinical Trials Compliance Licensing 52

The Pharma Data

OCTOBER 12, 2021

AZD7442 AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.

Trials 52

Trials Treatment Virus Disease 52

The Pharma Data

OCTOBER 25, 2020

The UK government’s COVID-19 Vaccine Taskforce and a contract research company called Open Orphan announced a $13 million (£10 million) plan to test investigational COVID-19 vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes COVID-19. They will require regulatory and ethical approval.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

NOVEMBER 1, 2020

2, 2020 /PRNewswire/ — Corlieve Therapeutics today announced the closing of its seed financing led by Kurma Partners and IDinvest Partners, together with Pureos Bioventures. In addition, Corlieve has licensed REGENXBIO’s NAV AAV9 technology for the TLE program. PARIS , Nov. Maryland , US), a leading gene therapy company.

Therapies 52

Therapies Science Treatment Disease 52

The Pharma Data

NOVEMBER 2, 2020

GWACHEON, KOREA, November 02, 2020 /24-7PressRelease/ — The trial of Shincheonji Church of Jesus Chairman Man Hee Lee continued on October 21st as the court discussed the alleged violation of the Infectious Disease Prevention Act earlier this year.

Trials 52

Trials Licensing Licensing Virus 52

The Pharma Data

OCTOBER 30, 2020

30, 2020 /PRNewswire/ — The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial. About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. TARRYTOWN, N.Y. ,

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

JANUARY 24, 2021

It was run at nine hospitals in Brazil from May 8 to July 17, 2020. Transgene and BioInvent received approval from France’s national regulatory agency to begin a Phase I/IIa trial of Vaccinia virus BT-001 in solid tumors. It is a virus-based therapeutic vaccine that encodes neoantigens picked by NEC’s Neoantigen Prediction System.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

The Pharma Data

JANUARY 22, 2021

iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

JANUARY 3, 2021

Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the company’s lead product candidate, PBGM01, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of infantile GM1 gangliosidosis (GM1). About PBGM01.

Therapies 52

Therapies FDA Treatment Clinical Trials 52